Merrimack lung cancer drug fails in one mid-stage trial group

(Reuters) – Merrimack Pharmaceuticals Inc said one of three patient groups in a mid-stage trial of its experimental lung cancer drug failed to meet the main goal of improving survival rates after four months of treatment without the disease worsening. The company’s shares fell 7 percent in premarket trade. The group was administered the drug, MM-121, in combination with erlotinib, an approved cancer treatment, for non-small cell lung cancer. Erlotinib is marketed as Tarceva by Swiss drugmaker Roche Holding AG. …

Navidea cancer imaging agent may see wider use

(Reuters) – Navidea Biopharmaceuticals Inc said its cancer diagnostic agent was effective in identifying the first lymph node reached by the disease in patients with head and neck cancer, paving the way to expand its use in all solid cancers. The company said a safety monitoring committee recommended that the trial be stopped early due to the positive results. …

1 75 76 77 78 79 88